Free Trial

Lucid Diagnostics (LUCD) Competitors

Lucid Diagnostics logo
$1.58 -0.01 (-0.63%)
Closing price 03:58 PM Eastern
Extended Trading
$1.62 +0.04 (+2.53%)
As of 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LUCD vs. SMTI, AVR, RCEL, LUNG, ELMD, INGN, ZYXI, LAKE, DRTS, and OBIO

Should you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include Sanara MedTech (SMTI), Anteris Technologies Global (AVR), AVITA Medical (RCEL), Pulmonx (LUNG), Electromed (ELMD), Inogen (INGN), Zynex (ZYXI), Lakeland Industries (LAKE), Alpha Tau Medical (DRTS), and Orchestra BioMed (OBIO). These companies are all part of the "medical equipment" industry.

Lucid Diagnostics vs.

Lucid Diagnostics (NASDAQ:LUCD) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends.

Lucid Diagnostics received 15 more outperform votes than Sanara MedTech when rated by MarketBeat users. Likewise, 67.92% of users gave Lucid Diagnostics an outperform vote while only 58.33% of users gave Sanara MedTech an outperform vote.

CompanyUnderperformOutperform
Lucid DiagnosticsOutperform Votes
36
67.92%
Underperform Votes
17
32.08%
Sanara MedTechOutperform Votes
21
58.33%
Underperform Votes
15
41.67%

Sanara MedTech has a net margin of -10.71% compared to Lucid Diagnostics' net margin of -1,069.87%. Lucid Diagnostics' return on equity of 0.00% beat Sanara MedTech's return on equity.

Company Net Margins Return on Equity Return on Assets
Lucid Diagnostics-1,069.87% N/A -123.54%
Sanara MedTech -10.71%-19.86%-10.91%

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 8.8% of Lucid Diagnostics shares are owned by insiders. Comparatively, 54.1% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Sanara MedTech has higher revenue and earnings than Lucid Diagnostics. Sanara MedTech is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lucid Diagnostics$2.43M39.44-$52.67M-$1.14-1.42
Sanara MedTech$64.99M4.70-$4.30M-$0.99-35.30

Lucid Diagnostics has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.

Lucid Diagnostics currently has a consensus price target of $3.63, suggesting a potential upside of 124.46%. Sanara MedTech has a consensus price target of $47.00, suggesting a potential upside of 34.48%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Lucid Diagnostics is more favorable than Sanara MedTech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lucid Diagnostics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
Sanara MedTech
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Lucid Diagnostics had 3 more articles in the media than Sanara MedTech. MarketBeat recorded 3 mentions for Lucid Diagnostics and 0 mentions for Sanara MedTech. Lucid Diagnostics' average media sentiment score of 0.02 beat Sanara MedTech's score of 0.00 indicating that Lucid Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
Lucid Diagnostics Neutral
Sanara MedTech Neutral

Summary

Lucid Diagnostics beats Sanara MedTech on 12 of the 19 factors compared between the two stocks.

Get Lucid Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LUCD vs. The Competition

MetricLucid DiagnosticsSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$95.24M$4.68B$5.82B$9.18B
Dividend YieldN/A50.78%5.25%3.99%
P/E Ratio-1.4124.1124.8119.27
Price / Sales39.4462.29465.4979.23
Price / CashN/A50.9644.6537.93
Price / Book-3.446.777.635.18
Net Income-$52.67M$90.91M$3.19B$245.95M
7 Day Performance21.43%2.08%1.18%1.70%
1 Month Performance91.62%1.74%3.21%1.19%
1 Year Performance18.75%17.09%20.06%15.79%

Lucid Diagnostics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LUCD
Lucid Diagnostics
3.2963 of 5 stars
$1.58
-0.6%
$3.63
+129.4%
+16.9%$93.76M$2.43M-1.3970
SMTI
Sanara MedTech
2.291 of 5 stars
$35.02
-0.7%
$47.00
+34.2%
-10.0%$306.08M$64.99M-35.3760
AVR
Anteris Technologies Global
N/A$7.99
+1.9%
$16.50
+106.5%
N/A$287.16MN/A0.00138News Coverage
RCEL
AVITA Medical
1.4213 of 5 stars
$10.57
+20.4%
$18.00
+70.3%
-40.8%$277.15M$50.14M-4.74130Earnings Report
High Trading Volume
LUNG
Pulmonx
2.15 of 5 stars
$6.97
-5.6%
$12.75
+82.9%
-51.2%$275.25M$68.68M-4.74250Earnings Report
News Coverage
ELMD
Electromed
N/A$31.89
-4.0%
N/A+115.1%$269.79M$54.72M44.29160Analyst Downgrade
INGN
Inogen
2.5625 of 5 stars
$10.64
-0.2%
$7.00
-34.2%
+5.6%$253.45M$315.66M-4.731,030Short Interest ↑
ZYXI
Zynex
2.6827 of 5 stars
$7.54
-0.4%
$14.00
+85.7%
-39.7%$240.15M$184.32M50.271,100News Coverage
LAKE
Lakeland Industries
4.8445 of 5 stars
$24.03
-1.9%
$27.50
+14.4%
+48.6%$228.29M$124.69M-267.001,750Short Interest ↓
News Coverage
DRTS
Alpha Tau Medical
3.0709 of 5 stars
$3.14
+2.6%
$8.00
+154.8%
+1.3%$219.56MN/A-7.3080Positive News
Gap Up
OBIO
Orchestra BioMed
2.8641 of 5 stars
$5.67
+1.3%
$16.25
+186.6%
-7.8%$215.52M$2.76M-3.524News Coverage

Related Companies and Tools


This page (NASDAQ:LUCD) was last updated on 2/19/2025 by MarketBeat.com Staff
From Our Partners